Quest Diagnostics
1,100 hedge funds and large institutions have $22.2B invested in Quest Diagnostics in 2026 Q2 according to their latest regulatory filings, with 118 funds opening new positions, 426 increasing their positions, 350 reducing their positions, and 71 closing their positions.
66% more first-time investments, than exits
New positions opened: 118 | Existing positions closed: 71
57% more call options, than puts
Call options by funds: $96.4M | Put options by funds: $61.5M
22% more repeat investments, than reductions
Existing positions increased: 426 | Existing positions reduced: 350
10% more capital invested
Capital invested by funds: $20.1B → $22.2B (+$2.07B)
3% more funds holding
Funds holding: 1,067 → 1,100 (+33)
1.22% more ownership
Funds ownership: 93.34% → 94.56% (+1.2%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
+$144M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$89.6M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$53.5M |
| 4 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$40.6M |
| 5 |
PPF
PFA Pension Forsikringsaktieselskab
Copenhagen,
|
+$40.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$167M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$76.8M |
| 3 |
Goldman Sachs
New York
|
-$71.8M |
| 4 |
JP Morgan Chase
New York
|
-$64M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$58M |
DGX Hedge Fund Activity: Q2 2026 in Review
1,100 of the 8,274 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q2 2026, worth a combined $22.2B — up 10% from $20.1B a quarter earlier.
Buyers outnumbered sellers: 118 funds opened new DGX positions and 71 closed out — a net gain of 47 holders — while 426 added to existing stakes and 350 trimmed.
The largest buyer was Boston Partners, adding an estimated $144M. The largest seller was T. Rowe Price Associates, cutting an estimated $167M.
- 1,100 institutional investors held Quest Diagnostics (DGX) as of Q2 2026, up from 1,067 in Q1 2026.
- Funds reported $22.2B of Quest Diagnostics stock for Q2 2026, up 10% quarter-over-quarter.
- 118 funds opened new Quest Diagnostics positions in Q2 2026 and 71 closed out, a net change of +47 holders.
- The largest Quest Diagnostics buyer in Q2 2026 was Boston Partners, an estimated $144M added.
- The largest Quest Diagnostics seller in Q2 2026 was T. Rowe Price Associates, an estimated $167M sold.
Based on aggregated 13F filings for Q2 2026.